Puma Biotechnology (PBYI) Receives a Hold from Barclays


Barclays analyst Gena Wang maintained a Hold rating on Puma Biotechnology (NYSEArca: PBYI) yesterday and set a price target of $72. The company’s shares closed yesterday at $48.65, close to its 52-week low of $46.55.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 24.3% and a 54.8% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Sarepta Therapeutics, and Mirati Therapeutics.

Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $80.50, representing a 65.5% upside. In a report released yesterday, Cowen & Co. also reiterated a Hold rating on the stock with a $80 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $136.90 and a one-year low of $46.55. Currently, Puma Biotechnology has an average volume of 922.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts